（文章来源：每日经济新闻） 每经AI快讯，2月5日，港股生物医药板块震荡走高，诺诚健华(09969.HK)涨超4%，再鼎医药 (09688.HK)、药明康德(02359.HK)、药明生物(02269.HK)、复宏汉霖(02696.HK)等个股跟涨。 ...

Core Viewpoint - Mirxes, JingTai Technology, and Sigmar BioScience are collaborating to establish an AI-driven comprehensive system for early screening, diagnosis, and treatment of gastric cancer, aiming to enhance the accessibility and effectiveness of gastric cancer care in Asia [1][2]. Group 1: Collaboration and Strategy - The three companies will form a joint venture in China and Singapore to leverage their respective strengths in expanding the Asian market [1]. - JingTai Technology will participate as a strategic investor in Mirxes' new stock placement and will engage in deep technical cooperation [2]. Group 2: Technological and Medical Goals - The initiative aims to build a complete treatment cycle for gastric cancer over the next five years, focusing on early screening, diagnosis, and treatment [1]. - The project seeks to systematically reduce the burden of gastric cancer on patients and healthcare systems in China by 2031, addressing the high incidence and mortality rates associated with the disease [1]. Group 3: Market Context - Gastric cancer is a prevalent malignancy in Asia, with nearly half of global gastric cancer deaths occurring in this region; China reports over 350,000 new cases and more than 260,000 deaths annually [1]. - The lack of effective treatment options for difficult-to-treat subtypes, such as diffuse gastric cancer, highlights the critical need for improved early screening and timely intervention [1].

Core Viewpoint - The construction of the biopharmaceutical formulation industrial park in Mingxi, Fujian Province, is a significant step towards enhancing the local biopharmaceutical industry, focusing on high-end formulation enterprises and extending the value chain towards terminal products [1][2]. Group 1: Industrial Development - Mingxi has attracted 25 biopharmaceutical companies, creating a "string of pearls" effect in the industry [1]. - The region has established two distinctive industrial chains: one focusing on Taxus chinensis for anti-tumor raw materials and another on hexafluoroisopropanol and its derivatives [1]. - The collaboration among companies in the park has improved supply chain efficiency, reducing logistics costs and enhancing competitive advantages [1]. Group 2: Investment and Growth - By 2025, Mingxi aims to attract key projects in new business areas such as Marketing Authorization Holder (MAH) and Contract Research Organization (CRO), with a total investment of 2.78 billion yuan from six major projects [2]. - The accelerated construction of the biopharmaceutical formulation industrial park signifies a strategic shift from raw material output to terminal product output [2]. - The biopharmaceutical industry in Mingxi generated tax revenue of 293 million yuan, becoming a crucial driver for regional economic transformation and high-quality growth [2].

Core Insights - The relocation of Jenda Kyushu to a new facility in Zhongguancun Life Science Park marks a significant milestone for the company, which aims to translate innovations in brain science into practical applications [1] - The development of the International Precision Medicine Industrial Park is a key indicator of the ongoing upgrade of industrial capacity in Zhongguancun Life Science Park Phase III, which has attracted 30 companies for potential entry [2] Group 1 - Jenda Kyushu has moved to a new office and laboratory space in the International Precision Medicine Industrial Park, which spans 7.4 hectares and features 242,000 square meters of buildings [1] - The park includes 17 industrial combination spaces designed to facilitate the entire chain of operations from headquarters to R&D centers and production facilities [1] - The surrounding area offers 55 shared service platforms to support the accelerated transformation of innovative results [1] Group 2 - The completion of three standardized factory projects, including the International Precision Medicine Industrial Park, has released 650,000 square meters of industrial space in the life science park [2] - The Life Valley International Bioengineering Innovation Center has already attracted 15 innovative companies, with the fastest-moving company expected to start internal renovations and move in by April [2] - The focus for the Kexing High-Precision Achievement Transformation Base this year will be on constructing mRNA vaccine production facilities to expedite the transformation of vaccine research results [2]

Core Viewpoint - Junxingjian Capital has accelerated its investment strategy in the biomedical and advanced manufacturing sectors by successfully registering two new funds, expanding its fund matrix to eight [1][2] Group 1: Fund Overview - Junxingjian Capital's new funds include Qingdao Junxingjian Tai Fund, focusing on biomedical fields such as biomedicine, medical devices, and pharmaceutical R&D services [1] - The other fund, Zhaiguang Zhiyuan Fund, targets advanced manufacturing sectors including new materials, high-end equipment, and military technology [1] Group 2: Strategic Focus - The funds aim to discover value in innovative diagnostic technologies and high-end medical devices, particularly targeting companies with core technological barriers that are in critical clinical stages or early commercialization [1] - The advanced manufacturing fund emphasizes investment in innovative companies that enhance supply chain security and achieve import substitution, covering the entire innovation chain from basic materials to end equipment [1] Group 3: Company Growth and Ecosystem - Since its establishment in 2021, Junxingjian Capital has developed a full-cycle service system with over 600 million yuan in managed funds, investing in more than 20 quality enterprises, many of which are entering critical capitalization stages [2] - The dual fund registration reflects an upgrade in the strategic layout for hard technology and health sectors, leveraging the ecosystem of invested enterprises to connect them with supply chains, customers, and capital markets [2]

Core Viewpoint - Parkinson's disease (PD) is identified as a somato-cognitive action network disorder, suggesting that targeting the specific neural regulation of the somato-cognitive action network (SCAN) may improve treatment outcomes for PD symptoms [3][12]. Group 1: Research Findings - A study published in Nature reveals the key abnormal mechanisms of Parkinson's disease, highlighting it as a disorder of the somato-cognitive action network [3]. - The research team constructed a large clinical imaging dataset (n=863) to explore the role of SCAN in the pathophysiology and treatment of Parkinson's disease [8]. - Effective treatments, including deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS), showed a reduction in the hyperconnectivity of SCAN to subcortical structures [10][12]. Group 2: Treatment Implications - Targeting SCAN rather than effector-specific regions significantly enhances the effectiveness of TMS treatment, with results showing a twofold improvement [10]. - The study indicates that the alleviation of SCAN hyperconnectivity is a core aspect of the pathophysiology of Parkinson's disease and a marker of successful neuroregulatory treatment [12]. - New non-invasive or minimally invasive neuroregulatory approaches targeting cortical SCAN nodes may improve existing therapies like DBS and MRgFUS [12].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 胶质母细胞瘤 （GBM） ，是最致命的 原发性中枢神经系统癌症，对目前的免疫治疗手段表现出显著的抗性。其肿瘤微环境是一个免疫荒漠，充满着抑制性因 素，有效攻击肿瘤的 T 细胞少之又少，传统免疫疗法很难奇效，关键在于我们难以直接改变大脑的免疫状态。 脑膜 是保护大脑的一个三层结构保护膜，其最外层为 硬脑膜 ，近年来的研究显示，这是一个活跃的免疫监视中心，能够采样、检查 并呈递中枢神经系统 （CNS） 来源的抗原，激活 T 细胞免疫。因此，如果增强硬脑膜的功能，是否可以从外向内强化大脑的抗肿瘤免疫力？ 2026 年 2 月 4日，中山大学第一附属医院 张弩 教授团队联合北京大学 白凡 教授团队，在国际顶尖学术期刊 Cell 上发表了题为： Meningeal blood vessel blockage enhances antiglioblastoma immunity 的研究论文。 该研究开发了一种硬脑膜界面功能性调控的显微外科方法—— 脑膜血管阻断 （ meningeal blood vessel blockage， MBB） ，证实了该方法能够有效抑制 胶质 母细胞瘤 ...

Core Insights - The "296X" advanced manufacturing cluster is a key focus for the Qiantang District, with significant contributions from industries such as artificial intelligence and semiconductor manufacturing [1][2] - The district aims to achieve an industrial output value of 420 billion yuan this year, up from 405.8 billion yuan last year, indicating a strong growth trajectory [1][3] Industry Developments - Qiantang District is committed to developing key industrial clusters including "China Chip," "Smart Vehicles," "Biopharmaceuticals," and "New Chemical Materials," positioning itself as a benchmark for intelligent manufacturing and cluster development [2] - The district plans to push the artificial intelligence sector to achieve over 100 billion yuan in revenue during the 14th Five-Year Plan period, establishing itself as the leading area for AI manufacturing and innovation [2] Company Perspectives - Companies like Zhejiang Lijichun Storage Technology Co., led by Yu Xiao, are optimistic about the supportive policies for the semiconductor industry, emphasizing the need for continuous investment and technological advancement [1][2] - Hangzhou Junchen Robotics Co., led by Shao Bilu, is focusing on the intelligent upgrade of the chemical fiber textile industry and plans to expand into the intelligent recycling of waste textiles, showcasing the integration of AI in traditional sectors [2][3] Strategic Goals - The Qiantang District aims to build a modern industrial system with greater prominence and influence, solidifying its leading position in the provincial and municipal advanced manufacturing cluster framework [3] - Specific initiatives include enhancing automotive collaboration, accelerating the launch of new vehicle models, and developing a biopharmaceutical hub to ensure the introduction of innovative drugs and expand the biopharmaceutical industry to over 26 billion yuan [3]

Core Viewpoint - Federal Pharmaceutical (03933) shares increased by nearly 3%, currently trading at HKD 12.17 with a transaction volume of HKD 54.12 million, following the announcement of a significant regulatory milestone for its innovative drug UBT251 [1] Group 1: Company Developments - Federal Pharmaceutical announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., received implied clinical trial approval from the National Medical Products Administration of China for UBT251 injection, targeting moderate to severe obstructive sleep apnea (OSA) associated with obesity, effective February 2, 2026 [1] - UBT251 is recognized as China's first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist new drug, positioning the company prominently in the research field of this category of drugs [1] - The company aims to continue its focus on new product development, enhancing its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]

Group 1 - China Galaxy Asset is committed to integrating national strategic services with its core business, directing financial resources towards the pharmaceutical industry to support the "Strong Pharmaceutical Nation" mission and promote healthy development of the real economy [1] - China Galaxy Asset has implemented a market-oriented debt-to-equity swap to increase capital for Taizhou Pharmaceutical, facilitating the acceleration of high-quality industrial resource aggregation and enhancing its "R&D-incubation-industrialization" ecosystem [1] - Taizhou Pharmaceutical, a leading enterprise in Jiangsu Province, has been recognized as one of the top ten biopharmaceutical industrial parks in China, but faces pressure on its capital structure due to significant investment and long funding cycles in the construction of the pharmaceutical city [1] Group 2 - The debt-to-equity swap by China Galaxy Asset helps Taizhou Pharmaceutical reduce its asset-liability ratio and financial costs, fundamentally optimizing its capital structure and enhancing its operational capabilities and market competitiveness [2] - This initiative not only alleviates financial pressure on the enterprise but also strengthens its foundation for stable and healthy long-term development, serving as a model for local state-owned enterprises in their transformation [2] - The successful implementation of the debt-to-equity swap highlights China Galaxy Asset's role as a financial risk mitigator, social resource allocator, and service provider for the real economy, providing a reference model for financial services in the "Strong Pharmaceutical Nation" initiative [2]